Pharmaceutical Companies Turn to AscellaHealth for Consultative Business Model, Including Robust Pre-Commercialisation and Market Access Services
Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.
Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.
Manufacturers discover an experienced, trusted resource for a full range of services from pre-commercialisation and market access to distribution and fulfilment, custom compliance programmes and outcomes tracking for enhanced patient outcomes.
As Specialty Pharmacy continues to gain market traction, biotech/pharmaceutical drug manufacturers are seeking innovative approaches to effectively launch new products, manage care coordination and offset the high cost of expensive medications for patients. Many are partnering with global healthcare and Specialty Pharmacy (SP) solutions providers, like AscellaHealth, for an end-to-end solution with capabilities that can more effectively and efficiently serve patients from diagnosis to medication access and throughout their entire treatment journey.
Because not all SP solution providers can deliver a full range of services, it is advantageous for manufacturers to collaborate with a single partner that can support the complete range of product launch milestones and specialised programs needed ensure patients have access to lifesavings treatments. These services span the complete launch of specialty products, from pre-commercialisation through all stages of the product life cycle, including fulfilment and clinical outcomes tracking.
The comprehensive portfolio of services provided by AscellaHealth results in streamlined access to therapy, optimal clinical results and an enhanced patient journey. Moreover, these high-touch specialty pharmacy capabilities ensure increased medication access and better compliance rates so patients can achieve the best possible outcome and treatment experience.
The key to a successful launch for rare disease and specialty products is to gain market access and product uptake through identification of targeted patient populations and developing strong relationships with them, as well as payers and provider networks.
AscellaHealth offers deep global market expertise and a vast range of capabilities to pharmaceutical manufacturers for a multi-pronged, productive market entry with the benefit of working with a single partner, alleviating the administrative burdens of managing multiple vendors.
Range of Critical Services for Biotech and Pharma Manufacturers
AscellaHealth’s customisable suite of services includes:
- Outsourced market access capabilities and payer expertise
- Wholesale, exclusive distribution and third-party logistics services
- International specialty pharmacy fulfilment
- Clinical patient support/Hub services
- Outcomes tracking and data analytics
- Pharmaceutical financial solutions & copay assistance programmes
Access
Product commercialisation and outsourced market access services ensure that specialty patients have access to the therapies they need when they need them most. AscellaHealth has the deep payer expertise to negotiate with payers on behalf of drug manufacturers, ensuring seamless access to therapies, while optimising outcomes for rare and ultra-orphan diseases. We can collaborate with a market access group or function as an outsourced team.
Communication
With comprehensive patient support and Hub capabilities that span the entire product life cycle and prescription process, our approach serves to streamline communications between prescriber, patient and pharmacy, decrease time to fill, increase patient engagement and optimise outcomes. Technology-based communication tools and algorithms are utilized by our expert call center to engage patients, break down barriers to communication and ensure optimal therapeutic outcomes.
Financial Assistance
To further serve market stakeholders, our team also developed and implemented a suite of unique Financial Assistance programmes for high-cost gene/cell therapies and other expensive specialty medications. Other custom copay programme options include the important work of patient care coordinators who offer the broad specialty therapeutic expertise needed to rapidly identify copay assistance and other financial resources necessary for patients to start and stay on therapy as prescribed.
Single Vendor
What’s more, manufacturers reap the benefits of working with and managing a single vendor for all programme and drug launch milestones. This means the data they receive will be from one source and purely actionable. Manufacturers can choose only the services they need, whether it’s all of the capabilities or a la carte.
AscellaHealth is well ahead of the marketplace trend of manufacturers shifting away from multiple big box vendors and opting instead for an all-inclusive vendor which offers white-glove support and service.
Patient-First Approach
AscellaHealth utilizes a patient-first approach that puts the patient at the center of care with patient care coordinators who are well versed in all rare and Specialty conditions. We also offer dedicated, branded teams for each manufacturer. Such high-level care coordination strengthens communication, yields rich data for more informed decision-making and improves the overall patient experience. This approach also empowers clinical teams to seamlessly eliminate treatment gaps for the patient.
Our model helps support streamlined patient access to prescribed high-cost therapies for complex conditions and rare diseases, with drug therapy monitored for effectiveness, compliance and adherence to treatment that leads to optimised health outcomes.
Manufacturers should view partnering with AscellaHealth as an opportunity to ensure a successful drug launch inclusive of enhanced product access, compliance to therapy, increased brand loyalty and optimal patient outcomes.
Contact AscellaHealth to learn more about AscellaHealth’s completely customisable programmes and end-to-end solutions for Life Science Manufacturers.